Evaluation of the Express Plus Range

Status Recruiting

Clinical Trial Summary

A prospective, open label, acceptability study to evaluate PKU, MSUD, HCU, TYR and GA express plus in the dietary management of 40 patients with IEM. The following parameters will be assessed: adherence to prescribed dietary intakes, palatability, usability, gastrointestinal tolerance, clinically relevant routine biochemical parameters, timeframe to transition and contribution of the express plus range to overall protein substitute intake over a 28 day period.

Clinical Trial Description

This is a prospective acceptability study of the express plus range in 40 participants aged at least three years of age for the dietary management of IEM (PKU, MSUD, HCU, TYR and GA ). The study will involve a Transition Period where patients will build-up to at least one sachet of express plus per day. During the Transition Period, daily intake of express plus and the patient's other PS will be recorded, including the time taken to consume. The Transition Period will last a maximum of 6 weeks, after which the patient will enter a 28-day Evaluation Period. During the Evaluation Period, patients will continue to record intakes, as well as GI tolerance and a final evaluation of the product's palatability and usability. Some patients, likely adults, will not require a transition from their original protein substitute to at least one sachet of express plus. These patients can enter the Evaluation Period directly. The end of the 4-week Evaluation Period is defined as the participant's End of Study. Following this, participants will be followed up as per standard of care. Some of this standard of care data may be relayed to the sponsor for a maximum of 26 weeks. This will last for a maximum of 26 weeks and will involve the collection of routine phe and tyrosine levels, as well as amount of PS prescribed and taken. Information will also be collected from patients regarding the reasons for the success or indeed failure of transition to PKU express plus. This data will come from routine clinical contact and will be recorded by the HCP, rather than by the patient. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05051657
Study type	Interventional
Source	Vitaflo International, Ltd
Contact	Clinical Trials Vitaflo
Phone	+44 (0) 151 709 9020
Email	ClinicalTrialsTeam@Vitaflo.co.uk
Status	Recruiting
Phase	N/A
Start date	June 14, 2021
Completion date	April 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05998109` - PheCheck Feasibility Study
Not yet recruiting	`NCT04433728` - Life With Phenylketonuria. Adult Neurological Outcome of PCU Screened Patients From 1971 to 2002.
Completed	`NCT01209819` - Bone Mineral Density in Adults With Hyperphenylalaninemia	N/A
Active, not recruiting	`NCT05174559` - Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)	N/A
Not yet recruiting	`NCT04969809` - Comparison of Atherogenic Risk Factors and Efficacy of Nutritional Treatment Among Adult Phenylketonuria Patients	N/A
Recruiting	`NCT04404530` - Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
Recruiting	`NCT05827536` - Open-label, Randomized, 2-way Crossover, Monocentric, Controlled Study to Evaluate the Effect on Daily PHE Fluctuation of PKU GOLIKE Versus SoC in Patients With PKU.	N/A
Active, not recruiting	`NCT05971563` - Amino Acid Kinetics of GMP-AA in Healthy Human Volunteers	N/A
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Completed	`NCT04368624` - PKU Skin Stripping
Completed	`NCT04452513` - A Prospective Clinical Study of Phenylketonuria (PKU)
Completed	`NCT05497050` - The Effect of Nursing Empowerment Program	N/A
Completed	`NCT04943393` - Remote Neurocognitive and Psychological Assessment in PKU
Completed	`NCT05096988` - Evaluation of PKU Sphere Liquid	N/A
Not yet recruiting	`NCT06332807` - AAV Gene Therapy Clinical Study in Adult Classic PKU	Phase 1/Phase 2
Completed	`NCT00225615` - A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels	Phase 3
Recruiting	`NCT05128149` - Metabolic Control and Patient Well-being in Phenylketonuria: do Guidelines Make a Difference?
Terminated	`NCT05229549` - Study to Evaluate the Effect on Nitrogen Retention of Two Different Posology Schemes of PKU GOLIKE PLUS 3-16 and Free AAs in Patients With Phenylketonuria	N/A
Enrolling by invitation	`NCT05356377` - Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKU
Not yet recruiting	`NCT06337864` - Evaluating the Efficacy and Safety of Large Neutral Amino Acids in the Treatment of Classical Phenylketonuria	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of the Express Plus Range — express plus

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms